| Ημερομηνία | barcode | code | περιεχομενο | τιμή παραγωγός | χονδρική | λιανική |
|---|---|---|---|---|---|---|
| 05/2018 | 2801127901014 | 112790101 | THYRO-4 TAB 100MCG/TAB ΒΤx100 | 04.02 | 4.22 | 5.82 |
| 05/2018 | 2801127901021 | 112790102 | THYRO-4 TAB 100MCG/TAB BTx1 BOTTLE x30 | 1.38 | 1.44 | 1.98 |
| 05/2018 | 2801127902011 | 112790201 | THYRO-4 TAB 200MCG/TAB ΒΤx100 | 4.17 | 4.37 | 06.02 |
| 05/2018 | 2801127902028 | 112790202 | THYRO-4 TAB 200MCG/TAB BTx1 BOTTLE x30 | 1.42 | 1.49 | 02.05 |
| 05/2018 | 2801127903025 | 112790302 | THYRO-4 TAB 25MCG/TAB BTx1 BOTTLE x30 | 1.34 | 1.41 | 1.94 |
| 05/2018 | 2801127904015 | 112790401 | THYRO-4 TAB 50MCG/TAB BTx1 BOTTLEx100 | 3.98 | 4.17 | 5.75 |
| 05/2018 | 2801127904022 | 112790402 | THYRO-4 TAB 50MCG/TAB BTx1 BOTTLE x30 | 1.35 | 1.42 | 1.96 |
| 05/2018 | 2801127905012 | 112790501 | THYRO-4 TAB 75MCG/TAB ΒΤx1 BOTTLE x100 | 3.99 | 4.19 | 5.77 |
| 05/2018 | 2801127905029 | 112790502 | THYRO-4 TAB 75MCG/TAB BTx1 BOTTLE x30 | 1.36 | 1.43 | 1.97 |
| 05/2018 | 2801127906019 | 112790601 | THYRO-4 TAB 125MCG/TAB BTx1 BOTTLEx100 | 04.08 | 4.28 | 5.90 |
| 05/2018 | 2801127906026 | 112790602 | THYRO-4 TAB 125MCG/TAB BTx1 BOTTLE x30 | 1.40 | 1.46 | 02.01 |
| 05/2018 | 2801127907016 | 112790701 | THYRO-4 TAB 150MCG/TAB BTx1 BOTTLEx100 | 4.11 | 4.31 | 5.94 |
| 05/2018 | 2801127907023 | 112790702 | THYRO-4 TAB 150MCG/TAB BTx1 BOTTLE x30 | 1.40 | 1.47 | 02.03 |
| 05/2018 | 2801127908013 | 112790801 | THYRO-4 TAB 175MCG/TAB BTx1 BOTTLEx100 | 4.14 | 4.34 | 5.98 |
| 05/2018 | 2801127908020 | 112790802 | THYRO-4 TAB 175MCG/TAB BTx1 BOTTLE x30 | 1.41 | 1.48 | 02.04 |
Used to lower high cholesterol levels in the blood.
Dextrothyroxine is a antihyperlipidemic. The mechanism of action is not completely understood, but dextrothyroxine apparently acts in the liver to stimulate formation of low-density lipoprotein (LDL) and, to a much greater extent, to increase catabolism of LDL. This leads to increased excretion of cholesterol and bile acids via the biliary route into the feces, with a resulting reduction in serum cholesterol and LDL. Dextrothyroxine has no significant effect on high-density lipoproteins (HDL).
Symptoms of dextrothyroxine overdose are unknown.
For use alone or in combination with antithyroid agents to treat hypothyroidism, goiter, chronic lymphocytic thyroiditis, myxedema coma, and stupor.
Levothyroxine acts like the endogenous thyroid hormone thyroxine (T<sub>4</sub>, a tetra-iodinated tyrosine derivative). In the liver and kidney, T<sub>4</sub> is converted to T<sub>3</sub>, the active metabolite. In order to increase solubility, the thyroid hormones attach to thyroid hormone binding proteins, thyroxin-binding globulin, and thyroxin-binding prealbumin (transthyretin). Transport and binding to thyroid hormone receptors in the cytoplasm and nucleus then takes place. Thus by acting as a replacement for natural thyroxine, symptoms of thyroxine deficiency are relieved.
LD<sub>50</sub>=20 mg/kg (orally in rat). Hypermetabolic state indistinguishable from thyrotoxicosis of endogenous origin. Symptoms of thyrotoxicosis include weight loss, increased appetite, palpitations, nervousness, diarrhea, abdominal cramps, sweating, tachycardia, increased pulse and blood pressure, cardiac arrhythmias, tremors, insomnia, heat intolerance, fever, and menstrual irregularities.
Bioavailability varies from 48% to 80%. Human studies have confirmed the importance of an intact jejunum and ileum for levothyroxine absorption and have shown some absorption from the duodenum.
T<sub>4</sub>, 6 to 7 days. T<sub>3</sub>, 1 to 2 days.
Thyroid hormones are primarily eliminated by the kidneys.